A Whirlwind of Earnings Feedback
Keep your eyes peeled—Acadia Healthcare just made quite the splash, with shares skyrocketing by 23% as the broader market vaulted higher. The Nasdaq is having a good day too, up by 1.23%, but let’s not get lost in the noise. This is about ACHC, and they've hit us with some impressive fourth-quarter figures.
A Closer Look at the Numbers
Acadia's adjusted earnings came in at 7 cents, comfortably beating that consensus whisper of 6 cents. What’s more, they raked in $821.46 million in sales, climbing over expected estimates of $800.07 million. We’re looking at revenue that didn’t just meet—they exceeded—those high watermark expectations for the quarter, mainly thanks to a jump in volume growth. That’s the kind of momentum investors can get behind.
Racking Up the Metrics
When diving deeper into the performance metrics, things start to align pretty well. Sales have grown by 6.1% year-over-year, which is no small feat in today's economic climate. Same-facility revenue rose by 4.4%, propelled by a 3.1% bump in patient days and a modest 1.3% uptick in revenue per patient day. It’s always good to see increasing foot traffic, even if the company did have to deal with a 2% drag from closed facilities during the last 12 months.
"Our results for the fourth quarter reflect improved volume growth with year-over-year revenue growth of 6%,” said Debbie Osteen, CEO.
Potential Ahead
As for the numbers from those acute inpatient psychiatric facilities, they showcased a solid 10% increase year-over-year, which turned out to be a cornerstone of the reported fourth-quarter revenue of $451 million. Acute inpatient volumes increased by 6%. This growth draws clarity: the company is spreading its wings, expanding capacity in both new and existing facilities—a smart play that could yield long-term dividends.
What’s Next for 2026?
Looking forward, Acadia is steering the ship with some cautious optimism—guiding for revenues between $3.37 billion and $3.45 billion for 2026, against a consensus of $3.41 billion. However, they’re projecting adjusted earnings per share in a range of $1.30 to $1.55, which is notably below the consensus target of $1.75. This creates a bit of a mixed message as they brace for same-facility volume growth stagnant at 0% to 1%.
Quarterly Insights
Short-term outlook for the first quarter of 2026 tells a similar tale—expectations for adjusted earnings fall shy of Wall Street’s bullish estimate. They’re forecasting earnings at 25 to 30 cents against a consensus of 31 cents, along with sales pegged between $820 million and $830 million. Given these mixed signals, it’s reasonable to be cautious while factoring in the current conditions.
Analyzing the Momentum
Let’s talk charts—the stock is currently hanging out at 22.71% above its 20-day simple moving average. That’s a solid indicator of short-term momentum right there. The RSI reads 44.45 which suggests a neutral landscape—neither too hot nor too cold—which might be a warning sign to tread carefully if the MACD trails at 0.15, just below its signal line at 0.22, reflecting bearish pressure. This admixture of signals points to a rather indecisive market sentiment.
- Key Resistance: $22.50
- Key Support: $19.50
Analyst Vs. Market Action
For those who love to track analyst action, ACHC holds a Buy Rating, with an average price target set at $21.27. There's been a mix in recent analyst sentiment:
- Guggenheim: Buy (Lowers Target to $22.00) (Feb. 23)
- Jefferies: Downgraded to Hold (Lowers Target to $15.00) (Jan. 22)
- TD Cowen: Buy (Lowers Target to $22.00) (Jan. 16)
So, here we sit with ACHC up 23.06% at $21.13 during midweek trading. It’s a pivotal time for investors to consider if they want to jump into this surge or sit on the sidelines for more clarity.
